Healthcare entity
Every one of those 1 sits in a single category, market-trends. Of the tracked stories, 1 of 1 also mention Alkermes, the most common co-covered peer. Source depth averages 20 original sources per story, versus 4.7 across the same-window beat baseline.
Last mentioned: Feb 26, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, market-trends. Of the tracked stories, 1 of 1 also mention Alkermes, the most common co-covered peer. Source depth averages 20 original sources per story, versus 4.7 across the same-window beat baseline. The 7 average consequence score is above the beat benchmark of 5.6 in the same window. RxSight appears in 1 tracked Healthcare story from February 26, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 41 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering RxSight. Shared-story counts are live from our verified record — not editorial picks.
The Q4 2025 earnings cycle for healthcare and health IT firms reveals a sector-wide shift toward AI-driven diagnostics and high-margin orphan drug commercialization. While medical device firms face cyclical equipment sales challenges, specialized biotech and diagnostic players like Veracyte and Soleno are reporting record profitability and rapid market penetration.
RxSight is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
